Paragon Labs Hired Former Apogee Therapeutics Executives
The Boston-based firm appointed new leadership following the acquisition of Apogee by AbbVie.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that shifting leadership between related biotech companies serves the best interest of patients?
Paragon Labs has appointed former Apogee Therapeutics executives, including new CEO Michael Henderson, to its leadership team. This restructuring comes as the Boston-based firm continues its model of spinning out specialized biotech companies.
Why it matters
The company aims to apply clinical and regulatory expertise gained during the development of the antibody zumilokibart at Apogee Therapeutics to its current and future drug discovery programs.
Paragon Labs secured a $350 million private placement led by Fairmount to fund its combined operations. This capital is projected to support development programs through 2029.
The players
Michael Henderson
He is the newly appointed CEO of Paragon Labs and previously served as the head of Apogee Therapeutics.
AbbVie
It is a global biopharmaceutical company that acquired Apogee Therapeutics for $10.9 billion.
Fairmount
This investment firm founded Paragon Labs in 2021 and led the recent $350 million private placement.
Alaunos Therapeutics
This biotechnology company recently acquired Velaris Therapeutics, a spinout from Paragon Labs.
The details
Paragon Labs, founded in 2021, operates by spinning out biotechnology entities such as Velaris Therapeutics, which was recently acquired by Alaunos Therapeutics to pursue pulmonary hypertension treatments. The new leadership team includes Carl Dambkowski, Dan Mulreany, Matt Batters, and Emily Cox, all of whom transition from roles at Apogee Therapeutics.
Timeline
Fairmount founded Paragon Labs in 2021.
AbbVie announced the $10.9 billion acquisition of Apogee in June 2026.
Paragon Labs announced the new leadership appointments on October 13, 2026.
The $350 million private placement is expected to fund the company until 2029.
The Tech Race
This move reinforces the trend of modular biotechnology development, where firms like Paragon Labs isolate specific drug discovery programs into distinct entities. By importing executive talent from high-profile acquisitions, the firm aims to sustain its competitive edge in rapid drug advancement.
While the leadership change is corporate in nature, it affects the biotechnology investment landscape by shifting the allocation of capital for potential future therapies. Stakeholders and industry observers will monitor how this management shift influences the development timelines for future clinical treatments.
The takeaway
The consolidation of veteran executive talent suggests that Paragon Labs is prioritizing high-level regulatory and clinical execution to de-risk its current pipeline. This strategy reflects a broader industry shift toward leveraging proven leadership teams to maximize the chances of successful drug commercialization.
What happens next
The $350 million private placement funding is expected to support the company's research and development operations through 2029.
Further reading
For more information on the evolving local landscape, visit the Biotech section.
Live Poll
Do you trust that shifting leadership between related biotech companies serves the best interest of patients?
